Variant position: 50 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 933 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human RPAAGPFPGSQTSDTLPEVS AIPISL-----------DGLLFPRPCQGQDPS
Gorilla RPAAGPYPGSQTSDTLPEVS AIPISL-----------DGLL
Chimpanzee RPAAGPFPGSQTSDTLPEVS AIPISL-----------DGLL
Mouse RLDSGPFQGSQHSDVSSVVS PIPISL-----------DGLL
Rat RLDPDPFQGSQHSDASSVVS PIPISL-----------DRLL
Rabbit RPDPGPFQGSQTSEASSVVS AIPISL-----------DGLL
Chicken AP---PSRG--------EAE GIDVAL-----------DGLL
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 933 Progesterone receptor
1 – 566 Modulating, Pro-Rich
1 – 164 AF3; mediates transcriptional activation (in isoform B)
1 – 157 Disordered
1 – 594 Missing. In isoform 3.
1 – 164 Missing. In isoform A.
17 – 635 Missing. In isoform 4.
55 – 55 L -> A. Reduces transcriptional activation; when associated with A-58 and A-59.
58 – 58 L -> A. Reduces transcriptional activation; when associated with A-55 and A-59.
59 – 59 L -> A. Reduces transcriptional activation; when associated with A-55 and A-58.
NIEHS SNPs program;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS THR-50; VAL-120; LEU-186; ARG-301; THR-344; SER-444; LEU-529; PRO-536; VAL-651 AND LEU-865;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.